CYTR Stock | Buy or Sell? | News | Quote | Stock Forum | Friday,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
$CYTR CytRx Corp. CYTR Company Overview 

CYTR Overall Average: 40% Buy

Stock Message Board http://investorshangout.com/search?q=CYTR&...mp;yt1=Go!

Last Updated: Friday, December 13, 2013 11:10:56 PM

CytRx Corp. CYTR Current Price and Quotes
Last Price 5.72
Previous Close 6.12 Open 6.17
Daily Range 6.79 - 5.45 52wk Range 6.36 - 1.80
Volume 19,620,526 Dividend N/A
Average Vol (3m) 1,611,966 Yield N/A
CytRx Corp. CYTR
Company Information

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049

Phone: (310) 826-5648

CytRx Corp. CYTR
Not Available

CytRx Corp. CYTR
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Latest Report Sep 30, 2013 10-Q
CIK 0000799698
Fiscal Year End 12/31
OTC Marketplace Not Available
Profile Data

SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Mission Investor Relations
3645 Marketplace Blvd.
Atlanta, GA, 30344
United States


CytRx Corp. CYTR
CYTR Security Details

Share Structure

Market Value1 $104,518,776 a/o Dec 13, 2013
Shares Outstanding 41,975,412 a/o Oct 29, 2013
Float Not Available
Authorized Shares Not Available
Par Value  0.001
Shareholders

Shareholders of Record Not Available
Security Notes

New Issue=11-86 6,000,000 shs in units (3 shs Com & 3 Class A Warr 11-9-91) at $6 per unit by D.H. Blair & Co., Inc.
Capital Change=Capital Change=shs decreased by 1 for 4 split. Ex-date=02/06/1996. Rec date=02/06/1996. Pay date=02/06/1996.
Capital Change=shs decreased by 1 for 7 split. Ex-date=05/16/2012.
Short Selling Data

Short Interest 3,265,454 (-3.06%)
Nov 30, 2010
Significant Failures to Deliver  No
Transfer Agent(s)

American Stock Transfer & Trust Company

CytRx Corp. CYTR Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 100 250 100 9,500
Cost of Revenue - - - -
Gross Profit 100 250 100 9,500
Operating Expenses

Research and Development 12,685 15,491 8,507 7,542
Sales, General and Admin. 8,353 7,317 8,236 9,128
Non-Recurring Items - - - -
Other 114 96 108 475
Operating Income (21,052) (22,654) (16,751) (7,645)
Income From Continuing Operations

Add'l Income/Expense Items 3,090 8,327 17,159 2,325
Earnings Before Interest and Tax (17,962) (14,327) 408 (5,319)
Interest Expense - - - -
Earnings Before Tax (17,962) (14,327) 408 (5,319)
Income Tax 2 98 - (519)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (17,964) (14,425) 408 (4,800)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (17,964) (14,425) 408 (4,800)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (17,964) (14,425) 408 (4,800)

CytRx Corp. CYTR Recent News

Dec 13, 2013 Bullish Stocks Radar: Las Vegas Sands, Celsion Corporation Holdings, CytRx Corporation, Microsoft Corporation
Dec 11, 2013 Bullish Stocks Radar: CytRx Corporation, Echo Therapeutics Inc, Advanced Micro Devices, Inc, Baidu Inc
Dec 11, 2013 CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial
Dec 10, 2013 CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas
Dec 4, 2013 CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th, 2013
Nov 26, 2013 CytRx to Present at the Sixth Annual LD MICRO "Main Event" Conference in Los Angeles on December 3, 2013
Nov 20, 2013 CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin in Patients with Unresectable Glioblastoma Multiforme (Brain Cancer)
Nov 7, 2013 MissionIR Releases Exclusive Audio Interview With CytRx Management
Oct 31, 2013 CytRx Reports Further Positive Interim Data from Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas
Oct 29, 2013 CytRx Reports 2013 Third Quarter Financial Results

1
2
next >
Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 487

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 292

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 445

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 233

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 466

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 403

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 425

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 328

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 378

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 237

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading

Top 5 Most Recently Viewed Articles

Turkish Stock Market Faces Decline Amid Sector Losses

Updated Category News Views 437

Turkish Stock Performance Overview The stock market in Turkey experienced a noticeable decline recently, driven primarily by losses in critical sectors such as Banking, Food & Beverages, and Basic Metals. These losses have contributed to an overall decrease in stock values, painting a challenging picture for investors. BIST 100 Index Decline At the close of trading, the...

Continue Reading
TaxDome Achieves Recognition in CPA Practice Advisor Awards

Updated Category News Views 161

TaxDome Triumphs in CPA Practice Advisor Efforts TaxDome, a leading practice management solution specially designed for tax professionals and accounting firms, has received outstanding recognition in the 2025 CPA Practice Advisor Readers' Choice Awards. Winning seven accolades and securing two runner-up positions, this achievement underscores the trust and esteem that the...

Continue Reading
Citi's Positive Outlook for Grab Holdings: A Buy Recommendation

Updated Category News Views 135

Citi Reaffirms Buy Rating on Grab Holdings Inc. In a recent note, Citi has reinforced its Buy rating on Grab Holdings Inc. (NASDAQ:GRAB), maintaining a price objective of $5.00. Analysts at Citi anticipate that Grab will announce its third-quarter results around mid-November. The firm prepared adjustments to International Financial Reporting Standards (IFRS) revenue and...

Continue Reading
Exploring Unusual Options Activity for American Airlines Group

Updated Category News Views 231

Insights into American Airlines Group's Options Activity In the bustling world of finance, American Airlines Group (NASDAQ: AAL) has drawn attention due to a notable surge in bullish options trading. Recently, our in-depth analysis unveiled a series of unusual trades that are shaping investor sentiment around American Airlines Group. Understanding the Options Activity The...

Continue Reading
CTERA Revolutionizes Hybrid Cloud Storage with MCP Support

Updated Category News Views 156

CTERA Leads the Way in Hybrid Cloud Innovations CTERA, the frontrunner in Enterprise Data Services, has recently announced an exciting advancement that positions it as a pioneer in hybrid cloud storage: the native support for the Model Context Protocol (MCP). This integration allows the hybrid cloud platform to embed an MCP Server, facilitating secure connections to...

Continue Reading